These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4978385)

  • 1. Effects of clofibrate (Atromid S) on the thyroxine-binding capacity of thyroxine-binding globulin and free thyroxine.
    McKerron CG; Scott RL; Asper SP; Levy RI
    J Clin Endocrinol Metab; 1969 Jul; 29(7):957-61. PubMed ID: 4978385
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of clofibrate on serum thyroxine transport and free thyroxine levels.
    Barbosa J; Oliner L
    Metabolism; 1969 Feb; 18(2):141-7. PubMed ID: 4974848
    [No Abstract]   [Full Text] [Related]  

  • 3. Microbodies in experimentally altered cells. VI. Thyroxine displacement from plasma proteins and clofibrate effect.
    Azarnoff DL; Svoboda DJ
    Arch Int Pharmacodyn Ther; 1969 Oct; 181(2):386-93. PubMed ID: 4397540
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of chlorophenoxyisobutyrate (CPIB) on thyroid parameters.
    Hansen JM
    Acta Endocrinol (Copenh); 1969 Feb; 60(2):294-302. PubMed ID: 4979609
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of chlorphenoxyisobutyrate ('Atromid-S') on the biliary excretion and distribution of thyroxine in the rat.
    Osorio C; Walton KW; Browne CH; West D; Whystock P
    Biochem Pharmacol; 1965 Oct; 14(10):1479-81. PubMed ID: 4956027
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of a new hypolipidemic agents, MK-185, on serum thyroxine-binding globulin (TBG) and dialyzable fraction thyroxine.
    Davis PJ; Hsu TH; Bianchine JR; Morgan JP
    J Clin Endocrinol Metab; 1972 Jan; 34(1):200-8. PubMed ID: 4621464
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypolipidemic, uricosuric, and thyroxine-displacing effects of MK-185 (halofenate).
    Morgan JP; Bianchine JR; Hsu TH; Margolis S
    Clin Pharmacol Ther; 1971; 12(3):517-24. PubMed ID: 4936037
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of MK-185 on thyroid function.
    Ryan JR; Jain A; Maha GE; McMahon FG
    Clin Pharmacol Ther; 1971; 12(3):464-7. PubMed ID: 4105444
    [No Abstract]   [Full Text] [Related]  

  • 9. [A family with hereditary increase in thyroxine-binding globulin].
    Köbberling J; Emrich D; Herrmann SJ; Krüskemper HL; von zur Mühlen A
    Dtsch Med Wochenschr; 1972 Feb; 97(6):194-6. PubMed ID: 4110009
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of ethyl chlorophenoxyisobutyrate on thyroxine distribution, transport and metabolism in man.
    Musa BU; Ogilvie JT; Dowling JT
    Metabolism; 1968 Oct; 17(10):909-15. PubMed ID: 4971141
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of Regelan (Atromid-S) on serum lipids and platelet aggregation in occlusive arterial disease].
    Fischer M; Irsigler K
    Int Z Klin Pharmakol Ther Toxikol; 1968 Jan; 1(3):248-51. PubMed ID: 4880993
    [No Abstract]   [Full Text] [Related]  

  • 12. Some effects of clofibrate in hypothyroidism and on the metabolism of thyroxine.
    Harrison MT; Harden RM
    Scott Med J; 1966 Jun; 11(6):213-7. PubMed ID: 4164431
    [No Abstract]   [Full Text] [Related]  

  • 13. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
    Hutchison JC; Wilkinson WH
    Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypolipidemic agents--newly approved.
    Duncan GG
    Metabolism; 1967 Sep; 16(9):775-6. PubMed ID: 4860365
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical evaluation of MK-185: a new hypolipidemic drug.
    Sirtori C; Hurwitz A; Sabih K; Azarnoff D
    Lipids; 1972 Feb; 7(2):96-9. PubMed ID: 4551950
    [No Abstract]   [Full Text] [Related]  

  • 16. Clofibrate effect on catecholamine-induced metabolic changes in humans.
    Hunninghake DB; Azarnoff DL
    Metabolism; 1968 Jul; 17(7):588-95. PubMed ID: 4872374
    [No Abstract]   [Full Text] [Related]  

  • 17. Antilipaemic drugs and nephrotic hyperlipidaemia.
    Edwards KD
    Prog Biochem Pharmacol; 1972; 7():370-426. PubMed ID: 4567423
    [No Abstract]   [Full Text] [Related]  

  • 18. Raised free thyroxine values in patients with familial elevation of thyroxine binding globulin.
    Thomson JA; Meredith EM; Baird SG; McAinsh WR; Hutchison JH
    Q J Med; 1972 Jan; 41(161):49-56. PubMed ID: 4116044
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antilipidemic agents].
    Irsigler K; Flegel U
    Int Z Klin Pharmakol Ther Toxikol; 1971 Dec; 5(3):334-40. PubMed ID: 5148890
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of dehydroepiandrosterone and Atromid in patients with hyperlipaemia.
    Felt V; Stárka L
    Cor Vasa; 1966; 8(1):40-8. PubMed ID: 4160021
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.